Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342] Draft guidance Technology appraisal guidance 6 February 2025 Capivasertib with fulvestrant ...

NICE, in collaboration with other international health technology assessment agencies, has published a new report which ...

Healthy eating and weight management in pregnancy, and healthy eating in children up to 5 years: the care you should expect Eating well before, during and after pregnancy means that both mother and ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee A. Committee members are asked to declare any interests in the perioperative ...

Durvalumab (Imfinzi, AstraZeneca) with platinum-based chemotherapy as neoadjuvant treatment, and then as monotherapy after surgery, is indicated for 'the treatment of adults with resectable (tumours ≥ ...

can be removed with surgery (resectable), and does not have genetic mutations in the EGFR gene or genetic mutations called rearrangements in the ALK gene. Your healthcare professionals should give you ...

If you’re commenting for an organisation, your organisation needs to be registered as a stakeholder. Not eligible? Contact the stakeholder organisation that most closely represents your interests and ...

Your organisation needs to be registered as a stakeholder before we can accept comments. Not eligible? Contact the stakeholder organisation that most closely represents your interests and pass your ...

Tools to help you put the guidance into practice.

Evidence on interventions to improve the uptake of folic acid supplementation before and during pregnancy showed mixed findings. Overall, information provision and education interventions compared ...

NICE is unable to make a recommendation about the use in the NHS of andexanet alfa (Ondexxya) for reversing anticoagulation in adults with intracranial haemorrhage. This is because AstraZeneca did not ...